News

On September 10th, Li Li, the director of the National Medical Products Administration, met with a delegation led by Cai Ruiwen, the director of the Health Sciences Authority of Singapore, in Beijing. Both sides conducted in-depth exchanges on further strengthening cooperation in the regulation of pharmaceuticals and medical devices between China and Singapore. Li Li introduced the work of drug regulation in China and the development of the pharmaceutical industry. He stated that in recent years, the National Medical Products Administration has consistently adhered to ensuring the quality and safety of drugs as its fundamental responsibility, continuously deepening the reform of the drug review and approval system, strengthening the construction of drug regulatory capabilities, and comprehensively promoting the scientific, legal, international, and modern development of drug regulation. Cai Ruiwen introduced the functions of the Health Sciences Authority of Singapore, its drug regulation work, and its participation in international drug regulatory coordination, as well as the establishment of trust and cooperation mechanisms with relevant countries in the field of drug and medical device review. The two sides exchanged views on promoting mutual trust in drug and medical device regulation between China and Singapore, as well as the regulation of traditional Chinese medicine. Both parties agreed to further deepen practical cooperation in the field of drug regulation to jointly enhance the quality and effectiveness of drug regulation and better promote the health and well-being of the people of both countries